KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Accounts Payables (2018 - 2025)

Historic Accounts Payables for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $10.3 million.

  • Adaptive Biotechnologies' Accounts Payables rose 3966.81% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 3966.81%. This contributed to the annual value of $7.3 million for FY2024, which is 588.16% down from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Accounts Payables of $10.3 million as of Q3 2025, which was up 3966.81% from $6.9 million recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Accounts Payables peaked at $12.2 million during Q1 2024, and registered a low of $2.7 million during Q2 2022.
  • Moreover, its 5-year median value for Accounts Payables was $6.9 million (2025), whereas its average is $6.9 million.
  • In the last 5 years, Adaptive Biotechnologies' Accounts Payables plummeted by 5535.86% in 2022 and then skyrocketed by 23687.5% in 2023.
  • Over the past 5 years, Adaptive Biotechnologies' Accounts Payables (Quarter) stood at $3.3 million in 2021, then soared by 144.45% to $8.1 million in 2022, then dropped by 4.52% to $7.7 million in 2023, then decreased by 5.88% to $7.3 million in 2024, then soared by 41.32% to $10.3 million in 2025.
  • Its Accounts Payables stands at $10.3 million for Q3 2025, versus $6.9 million for Q2 2025 and $6.4 million for Q1 2025.